Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for DaVita Inc. (DVA : NYSE)
 
 • Company Description   
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.

Number of Employees: 76,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $142.55 Daily Weekly Monthly
20 Day Moving Average: 789,047 shares
Shares Outstanding: 75.50 (millions)
Market Capitalization: $10,762.53 (millions)
Beta: 1.11
52 Week High: $179.60
52 Week Low: $131.76
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 4.72% -0.01%
12 Week 1.80% -14.09%
Year To Date -4.68% -10.44%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2000 16TH STREET
-
DENVER,CO 80202
USA
ph: 720-631-2100
fax: 302-636-5454
ir@davita.com http://www.davita.com
 
 • General Corporate Information   
Officers
Javier J. Rodriguez - Chief Executive Officer and Director
Joel Ackerman - Chief Financial Officer and Treasurer
Christopher M. Berry - Chief Accounting Officer
Pamela M. Arway - Director
Charles G. Berg - Director

Peer Information
DaVita Inc. (CMTI)
DaVita Inc. (CMWLQ)
DaVita Inc. (AHG.)
DaVita Inc. (ROIX)
DaVita Inc. (M.DCE)
DaVita Inc. (DHSM)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-OUTP/HM CRE
Sector: Medical
CUSIP: 23918K108
SIC: 8090
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 75.50
Most Recent Split Date: 9.00 (2.00:1)
Beta: 1.11
Market Capitalization: $10,762.53 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $3.20 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $10.76 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 13.48% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 13.25
Trailing 12 Months: 15.13
PEG Ratio: 0.98
Price Ratios
Price/Book: -
Price/Cash Flow: 7.45
Price / Sales: 0.83
EPS Growth
vs. Year Ago Period: -15.97%
vs. Previous Quarter: -10.71%
Sales Growth
vs. Year Ago Period: 4.98%
vs. Previous Quarter: -2.16%
ROE
06/30/25 - -
03/31/25 - 176.11
12/31/24 - 115.48
ROA
06/30/25 - -
03/31/25 - 4.66
12/31/24 - 4.94
Current Ratio
06/30/25 - -
03/31/25 - 1.25
12/31/24 - 1.26
Quick Ratio
06/30/25 - -
03/31/25 - 1.20
12/31/24 - 1.21
Operating Margin
06/30/25 - -
03/31/25 - 6.20
12/31/24 - 6.68
Net Margin
06/30/25 - -
03/31/25 - 6.63
12/31/24 - 7.31
Pre-Tax Margin
06/30/25 - -
03/31/25 - 11.14
12/31/24 - 11.94
Book Value
06/30/25 - -
03/31/25 - -0.09
12/31/24 - 4.83
Inventory Turnover
06/30/25 - -
03/31/25 - 64.78
12/31/24 - 64.15
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 23.18
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - 96.49
 

Powered by Zacks Investment Research ©